Effect of Daily Short Message System (SMS) Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia (SMS)

March 23, 2010 updated by: AstraZeneca

Effect of Daily SMS Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia

This study is a 6-month, multicenter, randomized study to assess the effect of daily SMS reminders sent during 3 months in the adherence to oral antipsychotic treatment in stabilized outpatients with schizophrenia.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

339

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
      • Alicante, Spain
        • Research Site
      • Almeria, Spain
        • Research Site
      • Barcelona, Spain
        • Research Site
      • Burgos, Spain
        • Research Site
      • Cordoba, Spain
        • Research Site
      • Granada, Spain
        • Research Site
      • Leon, Spain
        • Research Site
      • Lerida, Spain
        • Research Site
      • Madrid, Spain
        • Research Site
      • Malaga, Spain
        • Research Site
      • Murcia, Spain
        • Research Site
      • Oviedo, Spain
        • Research Site
      • Palma Mallorca, Spain
        • Research Site
      • Salamanca, Spain
        • Research Site
      • Sevilla, Spain
        • Research Site
      • Tarragona, Spain
        • Research Site
      • Toledo, Spain
        • Research Site
      • Valencia, Spain
        • Research Site
      • Valladolid, Spain
        • Research Site
      • Zamora, Spain
        • Research Site
    • Barcelona
      • Berga, Barcelona, Spain
        • Research Site
      • Sabadell, Barcelona, Spain
        • Research Site
    • Cantabria
      • Santander, Cantabria, Spain
        • Research Site
    • Navarra
      • Pamplona, Navarra, Spain
        • Research Site
    • Zaragoza
      • Calatayud, Zaragoza, Spain
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Stabilized outpatients with a diagnosis of schizophrenia

Description

Inclusion Criteria:

  • Male or female patients older than 18 years
  • With a diagnosis of schizophrenia (DSM-IV TR criteria)
  • Stabilized out-patients
  • Under oral antipsychotic monotherapy

Exclusion Criteria:

  • Administration of a depot antipsychotic drug
  • Suicide risk

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Morisky Green Questionnaire
Time Frame: baseline, at months 3 and 6
baseline, at months 3 and 6

Secondary Outcome Measures

Outcome Measure
Time Frame
Clinical Global Impression- Schizophrenia (CGI-SCH)
Time Frame: baseline, at months 3 and 6
baseline, at months 3 and 6
Register of Adherence to Treatment (RAT)
Time Frame: baseline, at months 3 and 6
baseline, at months 3 and 6

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AstraZeneca

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2009

Primary Completion (Actual)

March 1, 2010

Study Completion (Actual)

March 1, 2010

Study Registration Dates

First Submitted

March 31, 2009

First Submitted That Met QC Criteria

March 31, 2009

First Posted (Estimate)

April 1, 2009

Study Record Updates

Last Update Posted (Estimate)

March 24, 2010

Last Update Submitted That Met QC Criteria

March 23, 2010

Last Verified

March 1, 2010

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NIS-NES-DUM-2007/3

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Schizophrenia

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe